Avita Medical Announces Financial Results for Third Quarter Fiscal 2016
(firmenpresse) - NORTHRIDGE, CA, and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 04/29/16 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced its financial results for the third quarter of fiscal 2016 which concluded on March 31, 2016.
Total ReCell sales for the third quarter of fiscal 2016 were 42% higher year-over-year
Asia Pacific increased sales 54% year-over-year; China and Australia/NZ increased 155% and 450%, respectively
EMEA sales for the fiscal third quarter were 31% higher than the previous year; UK increased 46% and Germany increased 104%
Owing to the sale of the respiratory business on February 4, resulting in only one month of sales from these products, and transition to the distributor model, the Company''s receipts from customers were 37% lower than the previous quarter
For the nine-month period ending March 31, 2016, total ReCell sales for the year increased 23% versus the same period a year ago
For the nine months, Asia Pacific was up 46% with Taiwan sales of $98k and China up 13%
EMEA was up 8% with UK ahead of last year''s nine-month period by 16%, France up 19% and Germany 171% higher
Revenue recognition from the BARDA agreement began during the quarter with inflows of $1.142 million
Avita''s fiscal 2016 third quarter provided a great start for the calendar year. Importantly, the Company completed patient recruitment of its pivotal U.S. trial of ReCell for use in the treatment of acute burns. The company remains engaged in dialogue with the FDA on how the timeline may be improved. In addition, Avita continued to strengthen its leadership team with three new board members that add commercialisation expertise, especially in the U.S. market as the Company works toward approval. Avita also progressed it growth plans in the EU with the launch of its new products, ReGenerCell™ and ReNovaCell™, and having achieved positive results from its EU study of ReGenerCell™ in an additional indication, chronic Venous Leg Ulcers (VLUs). Finally, during the quarter, the Company bolstered its opportunity to expand its market share in Asia by signing agreements with distributors in Japan and South Korea, as well as the largest healthcare group in China.
Adam Kelliher, Chief Executive Officer of Avita Medical, commented, "We continued to execute our strategic initiatives during the quarter to focus the company and streamline our operations. We are working to create a business that has the potential for long-term revenue growth through our pipeline of regenerative products and believe we are positioning ourselves to achieve our goals. We have already begun to see results of our efforts, with the first inflow of revenue from our contract with BARDA, which totalled over one million dollars and further supports our pivotal trial for ReCell in the U.S. This trial is well on its way, having completed patient recruitment early in the quarter. As we have stated, the U.S. is an important market for Avita and our progress to date provides us with a lot of confidence in our place in this market. There is a significant need in the U.S. for our technology and we continue to hear from potential patients on a regular basis regarding their interest and need for our products."
Mr. Kelliher continued, "Our global presence is also of significant importance and we have proven successful in our renewed efforts to expand our footprint. We have put into place agreements with distributors in key Asian markets including China, Japan, and South Korea. While we have already had a presence in China, our new relationship with the largest medical and healthcare group will enable us to market ReCell to a much broader base in this country. Additionally, entry into Japan and South Korea is a very exciting opportunity and we believe the experience and reach of the distributors we are working with will enable us to take advantage of this market. Finally, the EU continues to be a growing market for Avita and our regenerative products. We recently launched two new products, ReGenerCell and ReNovaCell, in the EU which will be marketed through our expanded distributor network in this region. Overall, the company has been extremely active and we look forward to growing our global business and helping patients who suffer from serious ailments with our novel technology."
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita''s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient''s own skin. The Company''s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrolment completion anticipated by the end of 2015. To learn more, visit .
1 This statement has been prepared under accounting policies, which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
2 This statement does give a true and fair view of the matters disclosed.
1. The quarterly report provides a basis for informing the market how the entity''s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.
6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
9.2 - itemised disclosure relating to acquisitions
9.4 - itemised disclosure relating to disposals
12.1(a) - policy for classification of cash items
12.3 - disclosure of restrictions on use of cash
13.1 - comparative information
3. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
Gemma How
Sue Charles
Phone +44 (0)20 7866 7860
David Burke
Investor
Relations
Kirsten Thomas
Public Relations
Phone: +1 (646) 536-7009 / +1 (508) 280-6592
/
Rudi Michelson
Investor Relations / PR
Phone: +61 3 9620 3333
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2016 - 00:43 Uhr
Sprache: Deutsch
News-ID 1431478
Anzahl Zeichen: 3283
contact information:
Contact person:
Town:
NORTHRIDGE, CA, and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM
Phone:
Kategorie:
Medical Devices
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 333 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Announces Financial Results for Third Quarter Fiscal 2016
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
